Children have a mild course of acute COVID-19 in most of the cases. However, a few non-controlled studies on children present an evaluation of long-term recovery from SARS-CoV-2 infection. Mostly, the studies were conducted on a small sample size with children aged between 0-17 years.
The study aimed to evaluate symptoms and duration of 'long COVID' in children.
Data collection was done through a nationwide cohort study with 37,522 RT-PCR verified SARS-CoV-2 infected children, aged between 0-17 years (response rate 44.9%). Further, the study also had a group of 78,037 children as control (response rate 21.3%). An electronic questionnaire was used to collect data.
It was obtained that symptoms lasting > 4 weeks were common among both SARS-CoV-2 children and controls. However, SARS-CoV-2 infected children with the age of 6-17 years reported symptoms more frequently than the control group (percent difference 0.8%).
The most reported symptoms among pre-school children were
Fatigue Risk Difference (RD) 0.05 (CI 0.04-0.06)
Loss of smell RD 0.01 (CI 0.01-0.01)
Loss of taste RD 0.01 (CI 0.01-0.02)
Muscle weakness RD 0.01 (CI 0.00-0.01)
However, in school children, respiratory problems RD 0.03 (CI 0.03-0.04), dizziness RD 0.02 (CI 0.02-0.03), chest pain RD 0.01 (CI 0.01-0.01) were also observed along with the above-mentioned symptoms.
Furthermore, children in the control group experienced significantly more concentration difficulties, headache, muscle and joint pain, cough, nausea, diarrhea and fever than SARS-CoV-2 infected.
In most of the cases, 'long COVID' symptoms resolve in children within 1-5 months. Therefore, it can be interpreted that long COVID in children is rare and mainly of short duration.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation